Lilly's new diet drug comes up short in trials

There may be a new obesity drug inarmacies, one that doesn't involve needles or shots. A new latestage clinical study showed Eli Liy's experimental pill cut weight by 11% in patients. But investors aren't cheering.In fact, shares fell on the news. Why. Wall Street was expecting the drug called Orphon to perform better and more in line with its injectable counterparts.For example, Novo Nordisk's blockbuster weight loss shot, WGOI, helped patients shed up to 15% of their body weight in trials. Lily's own shot ...